logo

Melinta Therapeutics, Inc (MLNT)



Trade MLNT now with
  Date
  Headline
9/3/2019 4:08:26 PM Melinta Therapeutics Appoints Jennifer Sanfilippo As Interim CEO And Director
8/9/2019 7:33:39 AM Melinta Therapeutics Names David Gill Chairman Of Board
7/16/2019 7:35:23 AM Melinta Therapeutics Expects Q2 Net Product Sales Of About $13.8 Mln
6/19/2019 7:43:52 AM Melinta Therapeutics Announces FDA Acceptance Of SNDA For BAXDELA For Community-Acquired Bacterial Pneumonia
12/19/2018 8:37:13 AM Melinta Announces Commitment For New Credit Facility Of Up To $135 Mln
12/19/2018 8:35:53 AM John Johnson Agrees To Become Permanent CEO Of Melinta Therapeutics
12/17/2018 7:34:10 AM Dova Pharmaceuticals Names David Zaccardelli President And CEO
11/27/2018 8:06:54 AM Melinta Therapeutics Granted European Commission Marketing Authorization For Vabomere
11/7/2018 7:14:52 AM Melinta Therapeutics Q3 Net Loss $27.9 Mln Or $0.50/Shr
10/31/2018 5:20:06 PM Melinta Therapeutics Appoints Bruce Downey To Board Of Directors
10/29/2018 8:07:55 AM Melinta Reports Positive Top-Line Results In Phase III Trial Of Baxdela For Treatment Of CABP
10/22/2018 8:08:18 AM Melinta Therapeutics Names John Johnson Interim CEO
10/5/2018 8:13:17 AM Melinta Therapeutics Publishes Findings From Orbactiv
10/2/2018 8:05:51 AM Melinta Therapeutics Publishes Complete Results From Phase III TANGO 2 Study Of Vabomere
10/1/2018 8:20:23 AM Melinta Therapeutics, Menarini Group Enter Commercial Agreement For Vabomere, Orbactiv And Minocin For Injection